506 results on '"Brouwers, Adrienne H."'
Search Results
2. Towards in vivo characterization of thyroid nodules suspicious for malignancy using multispectral optoacoustic tomography
3. Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
4. Optimisation of scan duration and image quality in oncological 89Zr immunoPET imaging using the Biograph Vision PET/CT
5. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial
6. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data
7. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
8. [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial
9. First-time imaging of [89Zr]trastuzumab in breast cancer using a long axial field-of-view PET/CT scanner
10. Advances and challenges in immunoPET methodology
11. Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
12. Convolutional neural networks for automatic image quality control and EARL compliance of PET images
13. Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function
14. Extending the clinical capabilities of short- and long-lived positron-emitting radionuclides through high sensitivity PET/CT
15. Digital PET systems
16. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism
17. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
18. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism.
19. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
20. Use of population input functions for reduced scan duration whole-body Patlak 18F-FDG PET imaging
21. The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors
22. Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology
23. Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening
24. Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for89Zr-Trastuzumab
25. A Novel and Generic Workflow of Indocyanine Green Perfusion Assessment Integrating Standardization and Quantification Toward Clinical Implementation
26. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
27. Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis
28. High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment
29. Ultra‐low dose CT scanning for PET/CT.
30. Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab.
31. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms
32. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
33. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk
34. Abstract 5611: LAG-3 PET imaging in patients with cancer before immune checkpoint inhibitor therapy
35. Supplementary Figure S2 from [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
36. Figure S1 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
37. Supplementary Data_clean from 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
38. Supplementary Table S1 and S2 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
39. Supplemental Material from 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors
40. Data from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
41. Supplementary Figure 1, Tables 1 - 4 from 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
42. Data from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
43. Supplementary Figures 3-4 from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
44. Supplementary Figure Legends 1-7 from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
45. Supplementary Figures 5-6 from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
46. Supplementary Figures 1-2 from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
47. Supplementary Figures 7-8 from VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment
48. The Diagnostic Value of 18F-FDG PET/CT Scan in Characterizing Adrenal Tumors
49. The Diagnostic Value of 18F-FDG PET/CT Scan in Characterizing Adrenal Tumors.
50. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.